StreetInsider.com News Articles

Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Tue, 17 Feb 2026 16:18:00 -0500

si-local-file:///var/storage/secattach/20260217/26013223.html

Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Tue, 17 Feb 2026 16:18:00 -0500

si-local-file:///var/storage/secattach/20260217/26013223.html

Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC

Tue, 17 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260217/26013113.html

Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC

Tue, 17 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260217/26013113.html

Form SCHEDULE 13G Adicet Bio, Inc. Filed by: Woodline Partners LP

Tue, 17 Feb 2026 15:21:00 -0500

si-local-file:///var/storage/secattach/20260217/26011615.html

Form SCHEDULE 13G Adicet Bio, Inc. Filed by: Woodline Partners LP

Tue, 17 Feb 2026 15:21:00 -0500

si-local-file:///var/storage/secattach/20260217/26011615.html

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Fri, 30 Jan 2026 07:00:00 -0500

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York.

Details of the event are as follows:
Date: Thursday, February 12, 2026
Time: 2:00p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Fri, 30 Jan 2026 07:00:00 -0500

Details of the event are as follows:
Date: Thursday, February 12, 2026
Time: 2:00p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Fri, 30 Jan 2026 07:00:00 -0500

Details of the event are as follows:
Date: Thursday, February 12, 2026
Time: 2:00p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available

Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Fri, 30 Jan 2026 07:00:00 -0500

Details of the event are as follows:
Date: Thursday, February 12, 2026
Time: 2:00p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available

Form SCHEDULE 13G Adicet Bio, Inc. Filed by: FRANKLIN RESOURCES INC

Thu, 29 Jan 2026 11:18:00 -0500

si-local-file:///var/storage/secattach/20260129/25914356.html

Form SCHEDULE 13G Adicet Bio, Inc. Filed by: FRANKLIN RESOURCES INC

Thu, 29 Jan 2026 11:18:00 -0500

si-local-file:///var/storage/secattach/20260129/25914356.html

Form 4 Adicet Bio, Inc. For: Jan 24 Filed by: Aftab Blake

Tue, 27 Jan 2026 16:47:00 -0500

si-local-file:///var/storage/secattach/20260127/25901486.html

Form 4 Adicet Bio, Inc. For: Jan 24 Filed by: Aftab Blake

Tue, 27 Jan 2026 16:47:00 -0500

si-local-file:///var/storage/secattach/20260127/25901486.html

Form 4 Adicet Bio, Inc. For: Jan 24 Filed by: Healey Don

Tue, 27 Jan 2026 16:46:00 -0500

si-local-file:///var/storage/secattach/20260127/25901481.html

Form 4 Adicet Bio, Inc. For: Jan 24 Filed by: Healey Don

Tue, 27 Jan 2026 16:46:00 -0500

si-local-file:///var/storage/secattach/20260127/25901481.html

Form 4 Adicet Bio, Inc. For: Jan 24 Filed by: Schor Chen

Tue, 27 Jan 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260127/25901472.html

Form 4 Adicet Bio, Inc. For: Jan 24 Filed by: Schor Chen

Tue, 27 Jan 2026 16:45:00 -0500

si-local-file:///var/storage/secattach/20260127/25901472.html

Form 4 Adicet Bio, Inc. For: Jan 24 Filed by: Harvey Brian Nicholas

Tue, 27 Jan 2026 16:44:00 -0500

si-local-file:///var/storage/secattach/20260127/25901453.html

Form 4 Adicet Bio, Inc. For: Jan 24 Filed by: Harvey Brian Nicholas

Tue, 27 Jan 2026 16:44:00 -0500

si-local-file:///var/storage/secattach/20260127/25901453.html

Adicet Bio Inc. (ACET) PT Raised to $50 at H.C. Wainwright

Wed, 21 Jan 2026 07:07:18 -0500

(Updated - January 21, 2026 7:07 AM EST)

H.C. Wainwright analyst Robert Burns raised the price target on Adicet Bio Inc. (NASDAQ: ACET) to $50.00 (from $9.00) while maintaining a Buy rating.

The analyst commented: "As we look ahead, we point out the following catalysts to investors, including: (1) a clinical data update in 1H26 for Adicet's CD20-targeted allogeneic gamma delta CAR-T cell therapy, prulacabtagene leucel (prula-cel, formerly ADI-001), in LN, SLE, and SSc, followed by an additional update in these indications in 2H26; (2) alignment with the FDA on the pivotal trial design for prula-cel in LN or LN/SLE in 2Q26,

Adicet Bio Inc. (ACET) PT Raised to $50 at H.C. Wainwright

Wed, 21 Jan 2026 07:07:18 -0500

(Updated - January 21, 2026 7:07 AM EST)

H.C. Wainwright analyst Robert Burns raised the price target on Adicet Bio Inc. (NASDAQ: ACET) to $50.00 (from $9.00) while maintaining a Buy rating.

Form 8-K Adicet Bio, Inc. For: Jan 07

Wed, 07 Jan 2026 08:30:00 -0500

si-local-file:///var/storage/secattach/20260107/25817498.html

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Wed, 07 Jan 2026 07:00:00 -0500

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ADI-001) in ongoing and future clinical studies

All seven cohorts now actively enrolling in Phase 1 autoimmune clinical program as first anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) patient is dosed in study

Next clinical update from Phase 1 study of prula-cel in autoimmune disease expected in 1H/2026; plan to provide additional clinical update from the study in 2H/2026

Exploring potential to reduce need for conditioning with ongoing Phase 1 trial in

Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

Wed, 07 Jan 2026 07:00:00 -0500

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ADI-001) in ongoing and future clinical studies
All seven cohorts now actively enrolling in Phase 1 autoimmune clinical program as first anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) patient is dosed in study
Next clinical update from Phase 1 study of prula-cel in autoimmune disease expected in 1H/2026; plan to provide additional clinical update from the study in 2H/2026
Exploring potential to reduce need for conditioning with ongoing Phase 1 trial in